Novel Therapies in the Management of Advanced Renal Cell Carcinoma (RCC): New Strategies and Options for Improved Patient Outcomes.
- Published in:
- Journal of Managed Care Medicine, 2018, v. 21, n. 2, p. 58
- By:
- Publication type:
- Article
Works matching IS 10941525 AND DT 2018 AND VI 21 AND IP 2
Results: 11
1
2
Effective Strategies and Clinical Updates in Pulmonary Arterial Hypertension.
- Published in:
- Journal of Managed Care Medicine, 2018, v. 21, n. 2, p. 63
- By:
- Publication type:
- Article
3
Advanced Insights into the Prevention, Treatment and Management of Alzheimer's Disease.
- Published in:
- Journal of Managed Care Medicine, 2018, v. 21, n. 2, p. 52
- By:
- Publication type:
- Article
4
Recent Barriers and Future Insights of Biosimilars.
- Published in:
- Journal of Managed Care Medicine, 2018, v. 21, n. 2, p. 48
- By:
- Publication type:
- Article
5
Understanding Appropriate Treatments to Prevent and Manage Chemotherapy-Induced Nausea and Vomiting.
- Published in:
- Journal of Managed Care Medicine, 2018, v. 21, n. 2, p. 44
- By:
- Publication type:
- Article
6
New Frontiers in Metastatic Melanoma: A Closer Look at the Role of Immunotherapy.
- Published in:
- Journal of Managed Care Medicine, 2018, v. 21, n. 2, p. 40
- By:
- Publication type:
- Article
7
Exploring the Role of PCSK9 Inhibitors in the Reduction of LDL-C in Patients with Dyslipidemia.
- Published in:
- Journal of Managed Care Medicine, 2018, v. 21, n. 2, p. 27
- By:
- Publication type:
- Article
8
New Horizons in the Diagnosis and Management of Idiopathic Pulmonary Fibrosis (IPF).
- Published in:
- Journal of Managed Care Medicine, 2018, v. 21, n. 2, p. 23
- By:
- Publication type:
- Article
9
What's New in CFTR Modulator Therapy in the Management of Cystic Fibrosis.
- Published in:
- Journal of Managed Care Medicine, 2018, v. 21, n. 2, p. 19
- By:
- Publication type:
- Article
10
Optimizing Treatment Strategies in the Management of HIV/AIDS: Individualizing Therapy for Improved Patient Outcomes.
- Published in:
- Journal of Managed Care Medicine, 2018, v. 21, n. 2, p. 14
- By:
- Publication type:
- Article
11
There are several treatment options for castration-resistant prostate cancer (CRPC). The order in which to use these agents is not well defined, so selection is dependent on clinical symptoms and the adverse effect profiles of the agents. Molecular testing is becoming more common with CRPC and will likely be used in the future for therapy selection.
- Published in:
- Journal of Managed Care Medicine, 2018, v. 21, n. 2, p. 9
- By:
- Publication type:
- Article